Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
24-week Open-label Study of Oxcarbazepine (Trileptal) Monotherapy in Children With Partial Seizures
2015-004465-87Phase 4
- Sponsor
- Novartis
- Start
- May 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of oxcarbazepine in epilepsy, sponsored by Novartis. Primary endpoint: Rate of response (≥30% seizure frequency reduction).
02
Drugs
oxcarbazepine
03
Conditions
epilepsy
Beyond the preview
Go deeper on 2015-004465-87.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004465-87.